DSGN Design Therapeutics, Inc.

Overview and Growth

In fiscal 2025, Design Therapeutics, Inc. recorded $0.00 of revenue, net loss of $69.79M, and an operating cash outflow of $54.36M. Diluted earnings per share were -$1.22, translating the period’s attributable earnings into the amount reported for each diluted share. Diluted shares averaged 57.33M; this is the reported share base over which the company’s diluted per-share earnings were spread. Compared with 56.59M diluted shares in fiscal 2024, the current 57.33M base was 1.3% higher. Total assets stood at $226.20M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

The company recorded an operating loss of $79.47M after the reported operating expense base. After all below-operating-line items, the company recorded a net loss of $69.79M for the fiscal year. The company reported negative EBITDA of $78.84M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 32.8%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 30.9%, placing the bottom-line deficit against the company’s resource base. The net loss widened to $69.79M from $49.59M in fiscal 2024.

Liquidity and Capital Structure

At period end, the $226.20M asset base was financed through $13.70M of liabilities and $212.50M of equity. The near-term balance sheet paired $223.78M of current assets with $13.05M of current liabilities at the reporting date. Current assets covered current liabilities by 17.14x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $16.86M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 129.1% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Book equity represented 93.9% of total assets, quantifying the balance-sheet share supported by shareholder capital. Relative to total assets, liabilities measured 6.1%, complementing the separate equity-based view of the company’s capital structure. Measured against total assets, cash and equivalents represented 7.5%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $252.09M in fiscal 2024, the current asset base moved 10.3% and finished lower. Book equity was 12.2% lower than fiscal 2024 equity of $242.10M, showing how shareholder capital changed year over year. The reported cash balance changed 25.3% from $22.56M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $54.36M, rather than cash generation from operations. The company spent $193.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Negative free cash flow was $54.55M, leaving a cash deficit after capital spending and reducing financial flexibility. The free-cash-flow deficit equaled 24.1% of total assets, placing the cash shortfall against the company’s resource base. Cash absorbed by operations increased from $43.10M in fiscal 2024 to $54.36M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.